Program
Actinium-225
Also written as “[225Ac]Ac-FL-261”, “[225Ac]Ac-AKY-2519 (therapeutic)” and “[225Ac]Ac-AKY-1189 (therapeutic)”.
Its studies are mostly in Prostatic Neoplasms · Triple Negative Breast Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 6 companies.
Drug pageActinium-225: every studyMany companies study it; this page follows only the 10 they lead. All 13 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aktis Oncologyits history only | 33 open or running | phase 1since May 28, 2025 | May 28, 2025 | Dec 2027phase 1 · NCT07020117 |
| Alpha-9 Oncology USAits history only | 21 open or running | phase 1since Jun 27, 2025 | Jun 27, 2025 | Dec 2028phase 1 · NCT07661641 |
| AstraZeneca | 21 open or running | phase 3since Apr 22, 2026 | Nov 9, 2018 | Jun 4, 2029phase 3 · NCT07611110 |
| Eli Lillyits history only | 11 open or running | phase 1since Jan 3, 2024 | Jan 3, 2024 | Sep 2027phase 1 · NCT06229366 |
| Full-Life Technologies UKits history only | 11 open or running | phase 2since Sep 23, 2026 | Sep 23, 2026 | Jun 30, 2030phase 2 · NCT07873450 |
| PeptiDreamits history only | 11 open or running | phase 1since Jun 17, 2026 | Jun 17, 2026 | May 2029phase 1 · NCT07688187 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2018First study: phase 1 study in Endometrial NeoplasmsFirst studyNCT03746431 · 78 enrolled · United States, Australia, Canada
- Apr 22, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedNCT07611110 · 670 planned · United States, Australia, Austria and more
Ahead
- Jun 4, 2029Primary completion: phase 3 study in Prostatic NeoplasmsNCT07611110
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07611110Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Jun 4, 2029 | 670 |
| NCT03746431Endometrial Neoplasms · United States, Australia, Canada | 1 | Terminated | Dec 3, 2025 | 78 |
How it is read
Names in the registry
- “[225Ac]Ac-FL-261”, 3 entries
- “[225Ac]Ac-AKY-2519 (therapeutic)”, 2 entries
- “[225Ac]Ac-AKY-1189 (therapeutic)”, 1 entry
- “Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])”, 1 entry
- “[Ac-225]-PSMA-62 (mCRPC)”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
- Triple Negative Breast Neoplasms, 1 study
- Colorectal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.